Author

A. T. Larsson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

D. A. Largaespada· 2 shared A. C. Hirbe· 1 shared A. Calizo· 1 shared B. J. Keller· 1 shared C. A. Pratilas· 1 shared C. L. Moertel· 1 shared D. K. Wood· 1 shared E. Conniff· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. A. Largaespada

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors

K. B. Williams, A. T. Larsson, B. J. Keller, K. E. Chaney, R. L. Williams, T. A. Jubenville, M. M. Bhunia, G. M. Draper, C. L. Moertel, N. Ratner, D. A. Largaespada

This study identifies 23 compounds that selectively kill NF1-deficient Schwann cells and shows their efficacy in vivo, with synergy when combined with Selumetinib.

bioRxiv · Mar 25, 2024Cancer Biology

CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors

J. Wang, A. Calizo, L. Zhang, J. C. Pino, Y. Lyu, K. Pollard, X. Zhang, A. T. Larsson, E. Conniff, N. Llosa, D. K. Wood, D. A. Largaespada, S. E. Moody, S. J. Gosline, A. C. Hirbe, C. A. Pratilas

This study shows that combining SHP2 inhibitor TNO155 with CDK4/6 inhibitor enhances anti-tumor activity in MPNST by restoring RB function and overcoming resistance.

bioRxiv · Feb 2, 2023Cancer Biology